{"id":"drug-carfilzomib-lenalidomide-dexamethasone","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Anemia"},{"rate":"25-35","effect":"Thrombocytopenia"},{"rate":"20-30","effect":"Neutropenia"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Diarrhea"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Peripheral neuropathy"},{"rate":"15-20","effect":"Dyspnea"},{"rate":"5-10","effect":"Cardiac toxicity"},{"rate":"10-20","effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carfilzomib is a proteasome inhibitor that blocks protein degradation in cancer cells, triggering apoptosis. Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activity while also having direct anti-proliferative effects. Dexamethasone is a corticosteroid that provides additional anti-inflammatory and anti-proliferative activity. Together, these agents work synergistically to overcome drug resistance and improve outcomes in multiple myeloma.","oneSentence":"This three-drug combination kills multiple myeloma cells by inhibiting the proteasome, enhancing immune response to tumor cells, and suppressing tumor-promoting inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:04.731Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"},{"name":"Newly diagnosed multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06152575","phase":"PHASE3","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Multiple Myeloma","enrollment":492},{"nctId":"NCT04430894","phase":"PHASE2","title":"KRDI in Transplant-Eligible MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT04822337","phase":"PHASE1, PHASE2","title":"Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05-19","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT05675319","phase":"PHASE3","title":"Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2023-03-03","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT03934684","phase":"PHASE4","title":"Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-09-16","conditions":"Relapsed Refractory Multiple Myeloma","enrollment":101},{"nctId":"NCT01998971","phase":"PHASE1","title":"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-02-18","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT02405364","phase":"PHASE2","title":"Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2014-02","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT05669989","phase":"PHASE2","title":"International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Plasma Cell Myeloma","enrollment":70},{"nctId":"NCT03224507","phase":"PHASE2","title":"Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-03-14","conditions":"Multiple Myeloma","enrollment":123},{"nctId":"NCT02188368","phase":"PHASE2","title":"Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-07-07","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT02294357","phase":"PHASE2","title":"Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-12","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT02206425","phase":"PHASE1, PHASE2","title":"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Oncotherapeutics","startDate":"2014-09","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT03948035","phase":"PHASE3","title":"Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wuerzburg University Hospital","startDate":"2018-08-28","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":576},{"nctId":"NCT02336815","phase":"PHASE2","title":"Selinexor Treatment of Refractory Myeloma","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-05-26","conditions":"Multiple Myeloma","enrollment":202},{"nctId":"NCT03416374","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-18","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":45},{"nctId":"NCT04288765","phase":"PHASE3","title":"Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma","status":"WITHDRAWN","sponsor":"Grupo Cooperativo de Hemopatías Malignas","startDate":"2020-03-01","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT01402284","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-21","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT01554852","phase":"PHASE3","title":"Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2010-05","conditions":"Multiple Myeloma","enrollment":4420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Kyprolis"],"phase":"marketed","status":"active","brandName":"Drug: Carfilzomib + Lenalidomide + Dexamethasone","genericName":"Drug: Carfilzomib + Lenalidomide + Dexamethasone","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This three-drug combination kills multiple myeloma cells by inhibiting the proteasome, enhancing immune response to tumor cells, and suppressing tumor-promoting inflammation. Used for Relapsed or refractory multiple myeloma, Newly diagnosed multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}